ARVN
Arvinas, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.41
+1.05%Year over year
Reported trailing growth
- Revenue
- -15.0%
- EBITDA
- +103.2%
- EBIT
- +88.1%
- EPS
- +118.8%
- Free cash flow
- +47.7%
- Operating cash flow
- +47.8%
Forward estimates
Based on analyst estimates
- Revenue
- -80.2%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +26.0%
- EBITDA
- +60.7%
- EBIT
- +54.1%
- Net income
- +59.4%
- EPS
- +53.8%
- Free cash flow
- -5.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026